Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin (see Precautions). Abacavir should not be used in patients known to carry the HLA-B*5701 allele.